Breast cancer diagnosis for Giuliana Rancic

By Randee Dawn

Giuliana Rancic had to be dragged "kicking and screaming," as she put it, in to have a mammogram at the recommendation of her doctor. Sure, she was trying to have a baby via in vitro fertilization, but she was only 36 years old -- why should she bother?

E!'s celebrity news personality Giuliana Rancic tells TODAY's Ann Curry that she has breast cancer, a new struggle in her journey to have a baby.

It turned out to be one of the best decisions of her life, as Rancic revealed to TODAY's Ann Curry, that the mammogram showed she was in the early stages of breast cancer.

"It was just a kick in the stomach,"?Rancic recalled. "That was the hardest day ... (the emotions are) what you expect but so much more. It was incredible instant sobbing, and it was like the world just crashed down around me. I couldn't believe it, 36 years old, no family history."

Rancic?is personality on the E! Network and co-hosts "E! News" and "Fashion Police." She and husband Bill, season one winner of Donald Trump's "The Apprentice," married in 2007, and starting in 2010 the pair began appearing on a Style Network reality show, "Giuliana and Bill," which has detailed their struggles with infertility and attempts to conceive via IVF.

The last episode, which aired on September 26, showed her waving as she headed into a Denver clinic to get started on her next round of treatment. Not long after, she found out about the breast cancer diagnosis.

But as?Rancic told Curry, while this was her third try at IVF, it was the first time a doctor had insisted on a mammogram.

"He said, 'I don't care if you're 26 or 36, but I will not get you pregnant if possibly there's a small risk that you have cancer because the hormones will accelerate the cancer,'" said Rancic. "I never in my wildest dreams expected anything would be wrong."

Rancic had a message to share with women: "A lot of us think we're invincible ... but we have to start putting ourselves on the to-do list," she said. "I had a friend call me yesterday, and she said, 'I'm so sorry, can I do anything for you?' And I said, 'Just call your doctor tomorrow and make an appointment. That's what you could do for me.' ... I will be okay because I found it early."

Vitals blog: Experts say IVF not responsible for Rancic's breast cancer

That is the key. Rancic has found her breast cancer in an early stage, and expects all should be well, after some surgery and six and a half weeks of radiation treatments. And as for having a baby? That's on hold for just now, but Rancic says, "I'm not going to give up. I want that baby.... That baby will have saved my life."

Does this story make you want to get tested, or encourage a loved one to get tested? Share your thoughts on our Facebook page.

?

More in The Clicker:

Source: http://theclicker.today.com/_news/2011/10/17/8363134-es-giuliana-rancic-reveals-she-has-breast-cancer

ellen degeneres show ellen degeneres show david guetta david guetta work of art iphone update iphone update

Time to Raise Cain (Literally and Figuratively) (Powerlineblog)

Share With Friends: | | Politics - Top Stories Stories, RSS and RSS Feed via Feedzilla.

Source: http://news.feedzilla.com/en_us/stories/politics/top-stories/149243002?client_source=feed&format=rss

houston texans courageous courageous red tide red tide steelers florida gators

Watch the iPhone 4S Shoot Video Almost as Well as a $3000 DSLR (Updated: More Amazingness) [Video]

We know the iPhone 4S is a killer still camera—perhaps its greatest selling point—but how about video? Do the new guts and 1080p bump make a big difference? Yes. A giant yes. See just how amazing for yourself. More »

Source: http://feeds.gawker.com/~r/gizmodo/full/~3/BL71bJMeHSY/watch-the-iphone-4s-shoot-video-pretty-much-as-good-as-a-3000-dslr

osg osg temple grandin audrina patridge coleman graffiti study

NVIDIA intros 3D Vision 2 glasses with brighter field of view, comfier design

NVIDIA's 3D Vision is impressive and all, but one trade-off you'll have to accept when you put on those active shutter glasses is a markedly dimmer field of view than what you'd get if you settled for plain-Jane 2D gaming. Well, the outfit just unveiled the second generation of the technology -- appropriately named 3D Vision 2 -- and this go 'round it promises not to strain your vision quite so much. These shutter glasses have a lens that's 20 percent larger, promising a brighter experience. As an added perk, the frames have been rejiggered to be lighter and more flexible so that you can comfortably wear headphones without pinching your lobes. As for the newest 3D Vision monitors and laptops, those panels promise reduced ghosting, as well as 120GHz 2D gaming. In tandem with today's announcement, NVIDIA announced that a trio of products -- the Toshiba Qosmio X770 / 775, Toshiba Satellite P770 / P775 and ASUS's 27-inch VG278H 1080p monitor -- will support now 3D Vision 2. If a new rig's not in the cards, the company also assures us that these glasses will be backward compatible with older 3D Vision panels. Look for them this month in the form of either standalone frames ($99) or as part of a $149 kit. All those details and more in the PR tucked after the break.

Continue reading NVIDIA intros 3D Vision 2 glasses with brighter field of view, comfier design

NVIDIA intros 3D Vision 2 glasses with brighter field of view, comfier design originally appeared on Engadget on Fri, 14 Oct 2011 21:30:00 EDT. Please see our terms for use of feeds.

Permalink   |   | Email this | Comments

Source: http://www.engadget.com/2011/10/14/nvidia-intros-3d-vision-2-glasses-with-brighter-field-of-view-c/

starz kiwi kiwi our daily bread white pages osiris new york jets

UK medical group rejects new skin cancer treatment

LONDON (AP) ? An independent British medical watchdog says the first treatment proven to help people with the deadliest form of skin cancer is too expensive to be used by the U.K.'s health care system, a recommendation critics called a potential death sentence.

The drug, Bristol-Myers Squibb's Yervoy, has offered some hope to people with advanced skin cancers, though a study of patients with advanced, inoperable melanoma showed it extended survival only four months on average.

The National Institute for Clinical Excellence, or NICE, advised Friday that at a cost of 80,000 pounds ($126,600) Yervoy "could not be considered a cost-effective use" of health funds. A final decision is expected next month after a public consultation.

In the U.K., most medicines are paid for by the government, as long as they're recommended by the cost-efficiency watchdog. The agency commonly rejects expensive drugs, including recently advising against new treatments for prostate cancer, breast cancer, and multiple sclerosis, though patients and doctors are increasingly protesting the decisions.

The government usually adopts NICE's recommendations, meaning doctors in the government-funded health service cannot prescribe Yervoy without NICE's approval.

In its decision, NICE said it was not convinced by the evidence, saying the data for Yervoy, which works by stimulating the immune system to fight cancer, did not compare it to older drugs used to treat melanoma. NICE also said the trial was too short to know how long the drug's effects would last and raised concerns about the drug's side effects, including diarrhea, rash, fatigue and nausea, which they said could affect a patient's quality of life.

"We need to be sure that new treatments provide sufficient benefits to justify the significant cost (the health care system) is being asked to pay," said Sir Andrew Dillon, NICE's chief executive, in a statement.

Patient groups and charities slammed the decision, labeling it a "death sentence" for people with advanced skin cancer.

"The breakthrough that patients and clinicians throughout the U.K. have been waiting for arrived in the form of this drug," said patient advocacy group Factor 50 and the skin cancer charity SKCIN, in a statement. "To have come so close to a breakthrough and to be told no at this stage is truly devastating."

NICE does not usually approve any treatments that cost more than 30,000 pounds (US$47,492) to buy an extra healthy year of life, though it does occasionally make exceptions for lifesaving therapies.

In recent years, NICE has been forced to overturn a number of its original judgments after public outcry. "They actually reverse their decisions quite a lot," said Aparna Krishnan, a senior health care and pharmaceutical analyst at IHS Global Insight in London.

In 2005, the agency refused to recommend Alzheimer's drugs including Aricept. Public protests forced a reconsideration, and the drugs were finally recommended to all Alzheimer's patients last year. In addition, NICE has reversed its decisions on drugs including the kidney cancer drug Sutent, the flu drug Relenza, Velcade for blood cancer, and Herceptin for stomach cancer.

NICE has also been criticized for taking too long to recommend drugs. After Herceptin was first approved for breast cancer, the agency had to scramble to speed up its evaluation process after several women sued their hospitals to get treatment before advice was issued.

Some analysts said the spiraling cost of specialized cancer drugs would mean fewer hospitals and insurers willing to pay for them ? particularly those with cash-strapped public health systems.

"Drug companies, meet reality," said Erik Gordon, an analyst and professor at University of Michigan's Ross School of Business. "There isn't enough money to pay $100,000 for therapies that don't show massive benefits, unless there is a politically powerful patient advocacy group behind it."

Analyst Krishnan said she wasn't sure if patient and doctor protests would ultimately convince NICE to recommend Yervoy, but acknowledged it was a possibility. "They are in a very difficult position," she said. "They are increasingly just looking at the cost, but the pressure from the public can be very powerful."

_____

AP Business Writer Linda A. Johnson in Trenton, New Jersey, contributed to this report.

Associated Press

Source: http://hosted2.ap.org/APDEFAULT/f70471f764144b2fab526d39972d37b3/Article_2011-10-14-EU-MED-Skin-Cancer-Drug/id-dca6eb8d46874900b6b62facd4329100

ron white widespread panic widespread panic alcs alcs miguel cabrera josh hamilton

8 Signs Your College Major Might Not Be a Smart Choice

[unable to retrieve full-text content]

A college degree or some form of career training is crucial in today's job market. Beyond that, many students still seem mystified by - or resistant to - employment realities, in terms of which fields are hiring and which fields will actually pay well. If you're not sure what you should be studying, check your degree plans against these 8 warning signs. Anything you'd add to the list?

RELATED VIDEO:

Read More...

Source: http://www.huffingtonpost.com/2011/10/14/8-signs-your-college-majo_n_1010555.html

sand dollar sand dollar just dance 3 just dance 3 cliff lee cliff lee the raven

Business inventories and sales rose in August (AP)

WASHINGTON ? Businesses added to their stockpiles for a 20th consecutive month in August while sales rose for a third straight month. The increase suggests businesses were confident enough in the economy to keep stocking their shelves.

The Commerce Department says business inventories increased 0.5 percent in August, matching the July gain. Sales were up 0.3 percent in August following a 0.7 percent July increase.

A separate report Friday showed consumers stepped up their spending on retail goods in September. The 1.1 percent gain was the largest in seven months, a hopeful sign for the sluggish economy.

Source: http://us.rd.yahoo.com/dailynews/rss/economy/*http%3A//news.yahoo.com/s/ap/20111014/ap_on_bi_go_ec_fi/us_business_inventories

beanie wells west virginia football west virginia football alec baldwin alec baldwin erin brockovich prius c